Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04035486
Title A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

lung non-squamous non-small cell carcinoma

Therapies

Osimertinib

Carboplatin + Osimertinib + Pemetrexed Disodium

Cisplatin + Osimertinib + Pemetrexed Disodium

Osimertinib + Pemetrexed Disodium

Age Groups: adult | senior
Covered Countries USA | FRA | CAN


No variant requirements are available.